Published online 2019 December 23.

**Research Article** 

## The Relationship Between Promoter Methylation of RASSF1A Gene and Prognosis of Patients Affected with Breast Cancer in Khuzestan Province

Javad Mohammadi Asl<sup>1,\*</sup>, Farideh Ghanbari Mardasi<sup>2</sup>, Ghasem Saki<sup>1</sup>, Fakher Rahim<sup>3</sup>, Iran Rashidi<sup>4</sup>, Nastaran Ranjbari<sup>4</sup>, Parvin Kheradmand<sup>4</sup>, Mohammad Abromand<sup>5</sup>, Jasem ghavabesh<sup>6</sup> and Kolsoum Fazeli<sup>6</sup>

<sup>1</sup>Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

<sup>3</sup>Research Center of Thalassemia and Hemoglobinopathy, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

<sup>4</sup> Department of Pathology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

<sup>5</sup>Department of Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

<sup>6</sup>Genetic Counseling Center, Welfare Organization of Ahvaz, Ahvaz, Iran

corresponding author: Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: mohammadi-asl@ajums.ac.ir

Received 2019 July 18; Revised 2019 October 14; Accepted 2019 October 15.

## Abstract

**Background:** DNA methylation is one of the most frequent molecular changes that are associated with human cancers. Tumor suppressor genes are the important targets of hypermethylation in breast cancer and thus may result in cancer by deregulation of cell growth and division.

**Objectives:** The purpose of this research was to compare the methylation pattern of the RASSF1A gene in cancerous and normal tissues.

**Methods:** Twenty breast cancer patients with known clinicopathologic characteristics and 20 healthy women as control were studied for analysis of the methylation status of the RASSFIA gene promoter by methylation-specific polymerase chain reaction (MS-PCR) technique.

**Results:** The findings showed that the frequency of RASSF1A promoter methylation was in 15% of tumor tissues and 5% of normal tissues. These results indicate that there is no statistically significant relationship between the RASSF1A promoter methylation status of tumor tissues and normal tissues (P > 0.05).

**Conclusions:** Until now, the evidence for powerful methylation biomarkers is still incomplete and the recognized biomarkers require further validation.

Keywords: Breast Neoplasm, Epigenetic, Genetic, Tumor Suppressor Proteins, Case-Control Studies

## 1. Background

Breast cancer is the most frequent cancer and the leading cause of cancer death globally among women (1). Also in Iran, breast cancer is one of the most common cancers in women and 24.4% of all diagnosed cancers in women are breast cancer, which causes more than 1063 deaths annually (2). Because of a lack of definitive treatment to deal with this cancer, early and accurate diagnosis of the disease is critically important because it has a beneficial effect on reducing mortality in patients.

Epigenetic modification refers to both heritable changes in gene activity and expression and chromatin structure that occur without an alteration in the DNA sequence (3). DNA methylation is an epigenetic modification that directly affects DNA, which is the result of transfer of a methyl group from S-adenosyl-methionine (also known as SAM) to the cytosine. CpG islands (The CG island are regions with a high frequency of CpG sites and 'p' simply shows that 'C' and 'G' are connected by a phosphodiester bond) are considered to be a hallmark of the promoter regions of the genes. Extensive genomic analysis has shown that approximately 56% of the human promoters are associated with CpG islands. DNA methylation regulates gene expression with the effect on the upstream region of the gene (4). Changes in the pattern of methylation can lead to tumorigenesis (5).

The RASSF1A (Ras-associated domain family 1) tumor

Copyright © 2019, Gene, Cell and Tissue. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

<sup>&</sup>lt;sup>2</sup>Department of Midwifery, Shoushtar Faculty of Medicine Science, Shoushtar, Iran

suppressor gene is located on 3 p21.3, the short arm of chromosome 3, which acts as an inhibitor of the cycline D1 protein. Also, it plays a key role as an interactor with the proteins of the retinoblastoma family and negative regulator of cell proliferation through the G1/S inhibitor and mitotic checkpoint (6-10). Loss of expression of this gene occurs more frequently by hypermethylation that is capable of causing the development of human cancers (10).

## 2. Objectives

The aim of this study was to compare the DNA methylation pattern in the promoter region of the RASSFIA gene between cancerous tissues in the patients affected by breast cancer and normal tissues in the control group in Khuzestan province.

## 3. Methods

#### 3.1. Study Subjects

In the present study, 20 women were recruited from the Shafa and the Imam Khomeini hospitals in Ahvaz. Written informed consent was obtained from all participants for their tissues to be utilized for this study. Furthermore, twenty ages matched healthy women that had no history of cancer and autoimmune diseases were selected as the controls group. In the control group, the tissue of people who had come for cosmetic surgery was used. The sample collection procedure was approved by the University's Ethics Committee (Ahvaz Jundishapour University of Medical Sciences). The sample size was calculated using GPower V. 2.9.1.3 software. The most important inclusion criteria for study participants were female patient with primary tumor site on breast, no history of benign breast disease, no chronic inflammatory disorders, and the accessibility of the tissue along with clinicopathologic data of all patients. Female patients previously treated with SAM-interfering drugs, pregnancy, breastfeeding, as well as those missing clinicopathologic data were excluded from the study.

#### 3.2. DNA Extraction and Sodium Bisulfite Treatment of DNA

The DNA was extracted by the phenol-chloroform method and the extraction process was carried out according to the previous study (11). After extraction, the DNA-containing microtube was stored at -20°C.

Afterward, DNA was exposed to sodium bisulfate according to the method previously described (12). In brief, NaOH solution (2 M) was added to  $1 - 2 \mu g$  of genomic DNA. Denaturation of DNA started efficiently after incubating the mixture for 20 minutes at 37°C. Then about 30  $\mu$ L of 10 mM hydroquinone and 520  $\mu$ L of sodium bisulfite 3 M (PH = 5) were added to the denatured DNA and the surface was coated with a few drops of heavy mineral oil. Next, the solution was incubated at 50°C for 16 hours. Following the incubation, the methylated modified DNA was purified by the DNA purification kit of Roche. Subsequently, 5.5  $\mu$ L of 3 M sodium hydroxide (NaOH) was added to the modified DNA and incubated at room temperature for 5 minutes. The solution was neutralized by the addition of 100  $\mu$ L of 5 M ammonium acetate (NH4OAC). Finally, the DNA was precipitated in ethanol.

## 3.3. Methylation-Specific Polymerase Chain Reaction (MSP-PCR)

The methylation status of RASSF1A gene was investigated by using methylation-specific polymerase chain reaction (MS-PCR) technique. Two pairs of primers for methylated DNA (M pair) and for unmethylated DNA (U pair) were used that were previously described by Motevalizadeh Ardekani et al. (13), as shown in Table 1. The PCR temperature cycling conditions were as follows: initial denaturation at 95°C for 5 minutes, 40 cycles of 95°C for 30 seconds, annealing at 64°C for 25 seconds, 72°C for 25 seconds, and the final cycle was followed by extension at 72°C for 10 minutes. The PCR products were determined on 1% agarose gel. An image, presenting diverse methylation patterns, was captured (Figure 1).

Table 1. The Sequence of Primers and Product Size				
Primer	Sequence (5'→3')	Product Size (bp)		
RASSF1A-M	F: GGGTTTTGCGAGAGCGCG	- 169		
	R: GCTAACAAACGCGAACCG			
RASSF1A-U	F: GGTTTTGTGAGAGTGTGTTTAG	160		
	R: CACTAACAAACACAAACCAAAC	109		

#### 3.4. Statistical Analysis

Statistical analysis was performed with SPSS (version 25). P values were estimated using Fisher's exact test and P < 0.05 was considered statistically significant.

#### 4. Results

# 4.1. Methylation Analysis of a CpG Island in the Promoter Region of RASSF1A

The methylation status of the RASSF1A promoter was investigated on the DNA samples of 20 sporadic breast cancer tumors (with mean age  $48 \pm 6.7$  years) and 20 adjacent noncancerous tissues of the control groups (with mean

age 47  $\pm$  7.6 years). As presented in Table 2, the RASSF1A promoter methylation was not associated with the increased risk or prognosis of breast cancer (P = 0.6).

Table 2. Promoter Methylation Frequency of RASSFIA Gene in Breast Tumors and Normal Tissues<sup>a</sup>

RASSF1A Methylation Status	Breast Tumors	Normal Tissues	P Value
MM	3 (15)	1(5)	0.6
UM	4 (20)	5 (25)	1
UU	13 (65)	14 (70)	1
Total	20	20	

Abbreviations: MM, fully methylated promoter; UM, semi-methylated promoter; UU, fully unmethylated promoter. <sup>a</sup>Values are expressed as No. (%).

The methylated phenotype (MM) was more frequent in breast tumors (3/20 or 15%) compared to the healthy tissues (5/20 or 5%). Also, the semi-methylated phenotype (MU) was detected slightly more commonly in healthy tissues compared to the tumor tissues (25% vs. 20%), but no significant difference was detected between the two groups.

## 4.2. Association of RASSF1A Methylation with Clinicopathologic Parameters of Breast Cancer Patients

The analysis of the clinicopathologic data of the patients indicated no correlation between RASSF1A promoter methylation and the histopathological grade, familial history of breast cancer, familial history of other cancers, histology. Correlation of ER, PR, and HER2 markers with methylation was observed and RASSF1A methylation was correlated with ER in this locus but had no significant relationship with PR and HER2 (Table 3).



Figure 1. MS-PCR product of RASSFIA gene. L, marker; M, samples amplified with the primers for the methylated states; U, samples amplified with the primers for the non-methylated states; N, normal tissue samples; T, tumor tissue samples.

## 5. Discussion

One of the most common mechanisms for silencing cancer-related genes is the aberrant methylation of the promoter region, which resulted in downregulation of gene expression. It has been established that the loss of gene expression of important tumor suppressor and growth-regulatory genes that led to cancer can occur via CpG island methylation (14).

While many investigations have shown that CpG island methylation plays a key function in the development of breast cancer, the results were quite variable. The diverse outcomes may be correlated with the use of diverse DNA methylation markers and techniques of analysis. The aim of this study was to compare the DNA methylation pattern in the promoter region of the RASSFIA gene in cancerous and normal tissues. Also, we aimed to verify whether the methylation of RASSFIA gene involved in development of breast cancer correlated with particular clinicopathologic features and hormone receptor expression in patients affected by breast cancer in Khuzestan province.

Epigenetic inactivation of RASSF1A by methylation is identified to be common in carcinomas of lung, ovary, gastric, bladder, nasopharyngeal, and breast (7, 15-18). Based on previous studies, hypermethylation in the promoter region of this gene does not occur in the healthy breast tissue, so the promoter methylation of RASSF1A is a specific tumor phenomenon (6, 19).

The *RASSF1A* methylation frequency in tumoral and normal tissues was 15% and 5%, respectively (Figure 1), which was lower as compared to previous studies (19-24). Accordingly, our results were higher than the studies by Motevalizadeh Ardekani et al. (13) and Cho et al. (25) showed that the methylation level of RASSF1A was 9.5% and 4%, respectively. Interestingly, no significant difference was revealed in the methylation level of RASSF1A between the cases with breast cancer and the healthy control group.

The association of RASSF1A methylation in patients with breast cancer and healthy controls has been analyzed in several studies (24-33). Burbee et al. (19), Park et al. (24), and Kim et al. (30) detected significantly high frequency of RASSF1A methylation in breast carcinoma than control subjects. In contrast, Cao et al. (26) and Zmetakova et al. (32) revealed no significant difference in methylation frequencies of RASSF1A gene between breast cancer patients and normal controls, which was in line with our results. Furthermore, another study by Brooks et al. demonstrated no significant difference in frequencies of RASSF1A promoter methylation between breast cancer cases and healthy control groups (33). Actually, it is not easy to compare the results between the published data and the present study, where different methods have been used for methylation

Parameters	RASSFIA Methylation Status		P Value
	Non-Methylation (N = 17)	Methylation (N = 3)	
Estrogen receptor			0.04
Negative	1(5)	2(66)	
Positive	16 (95)	1(34)	
Progesterone receptor			1
Negative	4 (24)	1(34)	
Positive	13 (76)	2(66)	
Her2			1
Negative	10 (59)	2(66)	
Positive	7 (41)	1(34)	
Histopathological grade			0.7
I	2 (12)	-	
П	7 (41)	1(33.3)	
III	6 (35)	1(33.3)	
IV	2 (12)	1(33.3)	
Familial history of breast cancer			0.5
Negative	14 (82)	2(66)	
Positive	3 (18)	1(34)	
Familial history of other cancers			1
Negative	5 (30)	1(34)	
Positive	12 (70)	2(66)	
Histology			0.4
Ductal	15 (88)	2(66)	
Non-ductal	2 (12)	1(34)	

Table 3. Clinicopathologic Parameters of Breast Cancer Patients<sup>a</sup>

<sup>a</sup>Values are expressed as No. (%).

analysis and diverse CpG sites have been investigated. The exact number of methylated CpG sites as the potential biomarker for breast cancer risk still remains unclear.

We next investigated the correlation between RASSFIA promoter methylation and relevant clinicopathologic parameters including histopathological grade, familial history of breast cancer, familial history of other cancers, estrogen-receptor, progesterone-receptor, Her2 and histology. Our findings revealed that the frequency of *RASSFIA* methylation was not statistically different at low-grade and high-grade tumors that were in the same line with previous studies (18, 19, 21).

In contrast, we identified a significant correlation between RASSF1A promoter methylation and ER-negative, demonstrating that ER status can have an effect on epigenetic modifications of certain genes. The association of RASSF1A promoter methylation and ER negativity was detected in previous studies (19, 34), while some previous studies were inconsistent with our findings and they found a correlation between ER positivity and RASSF1A promoter methylation (23, 35-38). Also, we demonstrated no significant correlation between RASSF1A promoter methylation in tissue, PR and Her2 markers in our study that is in line with previous studies (20, 37).

Various results in previous studies and the present study can be due to technical problems in the MSP-PCR and DNA extraction from tumor cells, using different methods for evaluation of promoter methylation, different stages of tumor cells and heterozygosity of the alleles of this gene. Also, another limitation of our findings was the small sample size, which included 20 patients and 20 healthy controls. Therefore, large-scale multicenter prospective survey cohorts are required to confirm these findings.

In summary, the status of promoter methylation of the

RASSF1A gene in tissue included in our survey was unable to discriminate between breast cancer patients and healthy control groups. More prospective studies should be conducted to assess whether RASSF1A promoter methylation can be an appropriate biomarker for breast cancer early detection.

## Acknowledgments

We would also like to thank all of the participants for their contribution.

#### Footnotes

Conflict of Interests: There is no conflict of interest.

**Ethical Approval:** This study was approved by the Research Council and Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, with the code Eth.861.

**Funding/Support:** This study was supported by Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

**Informed Consent:** The participants were provided written informed consent.

## References

- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015;**65**(2):87-108. doi: 10.3322/caac.21262. [PubMed: 25651787].
- Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: An epidemiological review. *Breast J.* 2007;**13**(4):383–91. doi: 10.1111/j.1524-4741.2007.00446.x. [PubMed: 17593043].
- Fraga MF, Esteller M. Epigenetics and aging: The targets and the marks. *Trends Genet*. 2007;23(8):413–8. doi: 10.1016/j.tig.2007.05.008. [PubMed: 17559965].
- Jang HS, Shin WJ, Lee JE, Do JT. CpG and Non-CpG methylation in epigenetic gene regulation and brain function. *Genes (Basel)*. 2017;8(6):148. doi: 10.3390/genes8060148. [PubMed: 28545252]. [PubMed Central: PMC5485512].
- Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. *Cancer*. 2011;**117**(4):677–87. doi: 10.1002/cncr.25482. [PubMed: 20945317].
- Hesson LB, Cooper WN, Latif F. The role of RASSFIA methylation in cancer. *Dis Markers*. 2007;23(1-2):73–87. doi: 10.1155/2007/291538. [PubMed: 17325427]. [PubMed Central: PMC3850810].
- Jiang Y, Cui L, Chen WD, Shen SH, Ding LD. The prognostic role of RASSF1A promoter methylation in breast cancer: A metaanalysis of published data. *PLoS One*. 2012;7(5). e36780. doi: 10.1371/journal.pone.0036780. [PubMed: 22615811]. [PubMed Central: PMC3355150].
- Hu J, Li H, Shi T, Ma X, Wang B, Xu H, et al. Relationship between the expression of RASSFIA protein and promoter hypermethylation of RASSFIA gene in bladder tumor. *J Huazhong Univ Sci Technolog Med Sci*. 2008;28(2):182–4. doi: 10.1007/s11596-008-0217-3. [PubMed: 18480993].
- Fahraeus R, Olivares-Illana V. MDM2's social network. Oncogene. 2014;33(35):4365-76. doi: 10.1038/onc.2013.410. [PubMed: 24096477].

- Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. *Cancer Res.* 2005;65(9):3497–508. doi: 10.1158/0008-5472.CAN-04-4088. [PubMed: 15867337].
- Strauss WM. Preparation of genomic DNA from mammalian tissue. *Curr Protoc Mol Biol*. 2001;**Chapter 2**:Unit2 2. doi: 10.1002/0471142727.mb0202s42. [PubMed: 18265182].
- Eskandari-Nasab E, Hashemi M, Rafighdoost F. Promoter methylation and mRNA expression of response gene to complement 32 in breast carcinoma. *J Cancer Epidemiol.* 2016;**2016**:7680523. doi: 10.1155/2016/7680523. [PubMed: 27118972]. [PubMed Central: PMC4828546].
- Motevalizadeh Ardekani A, Shirani M, Hashemi A, Basiri Z, Rahmati Y, Nikbakhsh N, et al. Methylation status of NANOG1, RASSFIA, SFN, CASP8, WIF1,CTSL2 genes in Iranian breast cancer patients. *Iran South Med J*. 2017;19(6):940–50. doi: 10.18869/acadpub.ismj.19.6.940.
- Baylin SB, Ohm JE. Epigenetic gene silencing in cancer a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107–16. doi: 10.1038/nrc1799. [PubMed: 16491070].
- Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358(11):1148–59. doi:10.1056/NEJMra072067. [PubMed: 18337604].
- Jones PA, Baylin SB. The epigenomics of cancer. *Cell*. 2007;**128**(4):683– 92. doi: 10.1016/j.cell.2007.01.029. [PubMed: 17320506]. [PubMed Central: PMC3894624].
- Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the retinoblastoma tumorsuppressor gene. *Am J Hum Genet*. 1991;**48**(5):880–8. [PubMed: 1673287]. [PubMed Central: PMC1683063].
- Widschwendter M, Jones PA. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res., 8: 188-191, 2002. *Clin Cancer Res.* 2002;8(1):17–21. [PubMed: 11801535].
- Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. *J Natl Cancer Inst.* 2001;93(9):691–9. doi: 10.1093/jnci/93.9.691. [PubMed: 11333291]. [PubMed Central: PMC4374741].
- Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, Daoud J, et al. Aberrant methylation of RASSFIA is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol. 2010;136(2):203-10. doi: 10.1007/s00432-009-0649-6. [PubMed: 19657672].
- Hagrass HA, Pasha HF, Shaheen MA, Abdel Bary EH, Kassem R. Methylation status and protein expression of RASSFIA in breast cancer patients. *Mol Biol Rep.* 2014;41(1):57–65. doi: 10.1007/s11033-013-2837-3. [PubMed: 24253900].
- 22. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. *Clin Cancer Res.* 2004;**10**(18 Pt 1):6189–93. doi: 10.1158/1078-0432.CCR-04-0597. [PubMed: 15448006].
- Alvarez C, Tapia T, Cornejo V, Fernandez W, Munoz A, Camus M, et al. Silencing of tumor suppressor genes RASSFIA, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer. *Mol Carcinog.* 2013;**52**(6):475–87. doi: 10.1002/mc.21881. [PubMed: 22315090].
- Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, et al. Promoter CpG island hypermethylation during breast cancer progression. *Virchows Arch.* 2011;458(1):73–84. doi: 10.1007/s00428-010-1013-6. [PubMed: 21120523].
- Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, et al. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. *Anticancer Res.* 2010;30(7):2489–96. [PubMed: 20682973]. [PubMed Central: PMC3568974].

- Cao X, Tang Q, Holland-Letz T, Gundert M, Cuk K, Schott S, et al. Evaluation of promoter methylation of RASSFIA and ATM in peripheral blood of breast cancer patients and healthy control individuals. *Int J Mol Sci.* 2018;**19**(3):900. doi: 10.3390/ijms19030900. [PubMed: 29562656]. [PubMed Central: PMC5877761].
- Ahmed IA, Pusch CM, Hamed T, Rashad H, Idris A, El-Fadle AA, et al. Epigenetic alterations by methylation of RASSFIA and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA. *Cancer Genet Cytogenet*. 2010;**199**(2):96–100. doi: 10.1016/j.cancergencyto.2010.02.007. [PubMed: 20471512].
- Yazici H, Terry MB, Cho YH, Senie RT, Liao Y, Andrulis I, et al. Aberrant methylation of RASSFIA in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. *Cancer Epidemiol Biomarkers Prev.* 2009;**18**(10):2723-5. doi: 10.1158/1055-9965.EPI-08-1237. [PubMed: 19755643]. [PubMed Central: PMC3791602].
- Van der Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, et al. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. *Br J Cancer*. 2009;**100**(8):1277-86. doi: 10.1038/sj.bjc.6605013. [PubMed: 19367284]. [PubMed Central: PMC2676551].
- Kim JH, Shin MH, Kweon SS, Park MH, Yoon JH, Lee JS, et al. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. *Gynecol Oncol.* 2010;118(2):176–81. doi: 10.1016/j.ygyno.2010.04.016. [PubMed: 20466412].
- Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. *Breast Cancer Res.* 2013;15(1):R4. doi: 10.1186/bcr3375. [PubMed: 23320751]. [PubMed Central: PMC3672828].
- 32. Zmetakova I, Danihel L, Smolkova B, Mego M, Kajabova V, Krivulcik T,

et al. Evaluation of protein expression and DNA methylation profiles detected by pyrosequencing in invasive breast cancer. *Neoplasma*. 2013;**60**(6):635-46. doi: 10.4149/neo\_2013\_082. [PubMed: 23906298].

- Brooks JD, Cairns P, Shore RE, Klein CB, Wirgin I, Afanasyeva Y, et al. DNA methylation in pre-diagnostic serum samples of breast cancer cases: Results of a nested case-control study. *Cancer Epidemiol.* 2010;**34**(6):717–23. doi: 10.1016/j.canep.2010.05.006. [PubMed: 20627767]. [PubMed Central: PMC2956002].
- Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. *Breast Cancer Res.* 2008;10(3):R46. doi: 10.1186/bcr2098. [PubMed: 18485221]. [PubMed Central: PMC2481494].
- Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, Gonzalez K, et al. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. *Breast Cancer Res Treat*. 2012;**131**(1):197–205. doi: 10.1007/s10549-011-1712-y. [PubMed: 21837480]. [PubMed Central: PMC3576848].
- Li Y, Wei Q, Cao F, Cao X. Expression and promoter methylation of the RASSFIA gene in sporadic breast cancers in Chinese women. *Oncology Reports*. 2008;19(5):1149–53. doi: 10.3892/or.19.5.1149.
- Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, et al. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. *BMC Cancer*. 2010;**10**:378. doi: 10.1186/1471-2407-10-378. [PubMed: 20642860]. [PubMed Central: PMC2914707].
- Van der Auwera I, Bovie C, Svensson C, Trinh XB, Limame R, van Dam P, et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. *BMC Cancer*. 2010;**10**:97. doi: 10.1186/1471-2407-10-97. [PubMed: 20226036]. [PubMed Central: PMC2845117].